Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olvimulogene nanivacirepvec + chemotherapy
- Development stage
- Unknown
- Lead developer
- Genelux
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
- Administration
- Intravenous, Intraperitoneal, Intrapleural
01
Overview
GL-ONC1 (olvimulogene nanivacirepvec) is a genetically engineered oncolytic vaccinia virus (Lister strain) developed by Genelux Corporation. It is designed to selectively replicate within and lyse tumor cells while stimulating a systemic anti-tumor immune response. In combination with chemotherapy, such as platinum-based agents (cisplatin, carboplatin), GL-ONC1 aims to enhance therapeutic efficacy through synergistic cell killing and improved viral distribution. This combination has been primarily investigated for the treatment of platinum-resistant or refractory ovarian cancer, as well as other advanced solid tumors like head and neck cancer and malignant pleural effusion.
- Other names
- olvimulogene nanivacirepvec
02
Targets
DNA
Beyond the preview
Go deeper on olvimulogene nanivacirepvec + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olvimulogene nanivacirepvec + chemotherapy.